Appetite and General Nutritional DisordersPROTEINNCT04876495
The Effects of Whey, Rice and Potato pRotein isOlates on appeTite rEgulatIoN in Healthy Men
A study testing Whey protein isolate, Potato protein isolate and Rice protein isolate in people with Appetite and General Nutritional Disorders, run by University of Westminster at 1 site in United Kingdom.
Trial summary
INTRODUCTION: Global protein consumption has been increasing for decades due to changes in socio-economic demographics and consumer trends towards higher protein intake, which may be related to their health benefits in performance nutrition and appetite regulation. Read more about this study
- Who is it for?
- Ages 18 to 65 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Appetite and General Nutritional Disorders
- What is being tested?
- Whey protein isolate, Potato protein isolate and Rice protein isolate
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 20 Jul 2018to 19 Feb 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Males (18-65 years of age)
- Healthy subjects
Who cannot join
- <18 years or >65 years
- Consumption of >21 units of alcohol/week
- Dieters
- Any allergies/health issues related to items being ingested
- Any serious illnesses or those on medication
- Any illness affecting taste or appetite
Show all 10Show fewer
- Any gastrointestinal disorders
- Any eating disorders
- Any depression/mental disorders
- Smoking
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
University of Westminster
London, Greater London, W1W 6UW
About this study
Official title: Comparative Effects of Dairy and Plant-based Protein Intake on Acute Glucose Homeostasis and Appetite Regulation in Healthy Men
INTRODUCTION: Global protein consumption has been increasing for decades due to changes in socio-economic demographics and consumer trends towards higher protein intake, which may be related to their health benefits in performance nutrition and appetite regulation. The additional intake of protein often occurs in the form of supplements. One of the main ingredients used in sports and weight loss supplements are animal-derived proteins such as whey, which are of high quality, containing all the essential amino acids required in human nutrition with a high absorption rate. However, whey protein has a high environmental footprint, and it may contribute to insulin resistance in susceptible groups (e.g. obese, T2DM, insulin resistant, or those with sarcopenic obesity).
Rice and potato protein isolates are high-quality plant proteins containing all essential amino acids comparably to whey protein. These plant-derived proteins may provide a more sustainable and accessible alternative to animal-derived proteins for appetite regulation and weight management.
Read the detailed description
Intervention study with three treatment groups in a randomised, single-blind, triple crossover design.
Study population: Healthy male participants will receive three different isocaloric and -volumetric protein shakes prepared using whey, rice and potato protein powders on different trial days with at least a one-week washout period apart.
Biological samples (blood and saliva samples) are collected at various time points during the visit. Blood samples are collected at baseline 10 min prior (T-10), then at 30 min (T30), 60 min (T60), 120 min (T120) and at 180 min (T180) after protein shake consumption. Saliva samples are collected at baseline (T-10), then at every 30 minutes following protein shake consumption (T30, T60, T90, T120, T150, T180). In addition, pertinent questionnaires Visual Analogue Scale [VAS] for the assessment of satiety and VAS for the assessment of protein shakes' perception will be collected at T-10, T30, T60, T90, T120, T150, T180 and at T0, respectively
- Being tested
- Whey protein isolate, Potato protein isolate, Rice protein isolate
- Keywords
- nutraceutical, protein, whey, potato protein, rice protein, appetite, satiety, insulin, glucose, appetite hormone, GLP-1, PYY, supplement
- Medical subject headings
- Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Whey protein isolateDietary supplement
Instantized BiPRO® 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.
Other ingredients in the whey protein shake:
- Tropicana Trop50 Orange Juice 207mL
- Water 43 mL
- Sucralose 0.5g
The total energy 233.47Kcal.
Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study.
Potato protein isolateDietary supplement
Solanic®100 48g (equiv. 45.3g of total protein) presented to participants in a form of a shake.
Other ingredients in the potato protein shake:
- Tropicana Trop50 Orange Juice 250mL
- Sucralose 0.5g
The total energy 233.46Kcal
Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study.
Rice protein isolateDietary supplement
Oryzatein® Silk 90 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake.
Other ingredients in the rice protein shake:
- Tropicana Trop50 Orange Juice 183mL
- Water 67mL
- Sucralose 0.5g
The total energy 233.43Kcal
Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study.
| Study group | Role | What they receive |
|---|---|---|
| Whey protein | Active comparator | Whey protein isolate (45.5g total protein content) Receives: Dietary Supplement: Whey protein isolate |
| Potato protein | Active comparator | Potato protein isolate (45.3g total protein content) Receives: Dietary Supplement: Potato protein isolate |
| Rice protein | Active comparator | Rice protein isolate (45.5g total protein content) Receives: Dietary Supplement: Rice protein isolate |
What is being measured
The primary outcome is the main question the study is designed to answer.
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T-10)
Marker: glucose (mmol/L)
Measured: Glucose measured 10 minutes prior to protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T30)
Marker: glucose (mmol/L)
Measured: Glucose measured 30 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T60)
Marker: glucose (mmol/L)
Measured: Glucose measured 60 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T120)
Marker: glucose (mmol/L)
Measured: Glucose measured 120 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T180)
Marker: glucose (mmol/L)
Measured: Glucose measured 180 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T-10)
Marker: insulin (ng/mL)
Measured: Insulin measured 10 minutes prior to protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T30)
Marker: insulin (ng/mL)
Measured: Insulin measured 30 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T60)
Marker: insulin (ng/mL)
Measured: Insulin measured 60 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T120)
Marker: insulin (ng/mL)
Measured: Insulin measured 120 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T180)
Marker: insulin (ng/mL)
Measured: Insulin measured 180 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T-10)
Markers: glucagon-like peptide 1 (pM)
Measured: Glucagon-like peptide 1 measured 10 minutes prior to protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T30)
Markers: glucagon-like peptide 1 (pM)
Measured: Glucagon-like peptide 1 measured 30 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T60)
Markers: glucagon-like peptide 1 (pM)
Measured: Glucagon-like peptide 1 measured 60 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T120)
Markers: glucagon-like peptide 1 (pM)
Measured: Glucagon-like peptide 1 measured 120 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T180)
Markers: glucagon-like peptide 1 (pM)
Measured: Glucagon-like peptide 1 measured 180 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T-10)
Markers: peptide tyrosine tyrosine (pg/mL)
Measured: Peptide tyrosine tyrosine measured 10 minutes prior to protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T30)
Markers: peptide tyrosine tyrosine (pg/mL)
Measured: Peptide tyrosine tyrosine measured 30 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T60)
Markers: peptide tyrosine tyrosine (pg/mL)
Measured: Peptide tyrosine tyrosine measured 60 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T120)
Markers: peptide tyrosine tyrosine (pg/mL)
Measured: Peptide tyrosine tyrosine measured 120 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T180)
Markers: peptide tyrosine tyrosine (pg/mL)
Measured: Peptide tyrosine tyrosine measured 180 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T-10)
Markers: ghrelin (pg/mL)
Measured: Ghrelin (pg/mL) measured 10 minutes prior to protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T30)
Markers: ghrelin (pg/mL)
Measured: Ghrelin (pg/mL) measured 30 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T60)
Markers: ghrelin (pg/mL)
Measured: Ghrelin (pg/mL) measured 60 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T120)
Markers: ghrelin (pg/mL)
Measured: Ghrelin (pg/mL) measured 120 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T180)
Markers: ghrelin (pg/mL)
Measured: Ghrelin (pg/mL) measured 180 minutes post protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T-10)
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
Measured: Visual Analogue Scale for Appetite (VAS-A) collected immediately prior to protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T30)
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
Measured: Visual Analogue Scale for Appetite (VAS-A) collected 30 minutes after protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T60)
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
Measured: Visual Analogue Scale for Appetite (VAS-A) collected 60 minutes after protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T90)
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
Measured: Visual Analogue Scale for Appetite (VAS-A) collected 90 minutes after protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T120)
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
Measured: Visual Analogue Scale for Appetite (VAS-A) collected 120 minutes after protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T150)
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
Measured: Visual Analogue Scale for Appetite (VAS-A) collected 150 minutes after protein shake consumption
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T180)
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
Measured: Visual Analogue Scale for Appetite (VAS-A) collected 180 minutes after protein shake consumption
Secondary outcomes (1)
To assess the perception of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO®
Subjective analysis including: Visual Analogue Scale for Palatability (VAS-P). Scores range from 0 to 100 (the higher the score the lower the palatability)
Measured: VAS for Palatability collected immediately after protein shake consumption
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2021
- Study start20 Jul 2018
- Primary completion19 Feb 2021
- Study completion19 Feb 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Appetite and General Nutritional DisordersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- single-blind, randomised, triple crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Westminster
- Sponsor type
- University, hospital or other
- Collaborators
- Coventry University
- Responsible party
- Principal investigator, Mohammed Gulrez Zariwala, University of Westminster
- Investigators
- Mohammed Gulrez Zariwala, PhD, Principal investigator, University of Westminster
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04876495
- Sponsor's protocol ID
- VRE1516-1375
- Acronym
- PROTEIN
- Status last verified
- May 2021
- First submitted
- 28 Apr 2021
- Last updated
- 6 May 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Effects of Dairy and Plant-based Protein Intake on Acute Glucose Homeostasis and Appetite Regulation in Healthy Men
- ClinicalTrials.gov ID
- NCT04876495
- Acronym / sponsor ID
- PROTEIN / VRE1516-1375
- Keywords
- nutraceutical, protein, whey, potato protein, rice protein, appetite, satiety, insulin
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- University of WestminsterUniversity, hospital or other
- Collaborators
- Coventry University
- Study start
- 20 Jul 2018 (actual)
- Primary completion
- 19 Feb 2021 (actual)
- Study completion
- 19 Feb 2021 (actual)
- First posted
- 6 May 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
INTRODUCTION: Global protein consumption has been increasing for decades due to changes in socio-economic demographics and consumer trends towards higher protein intake, which may be related to their health benefits in performance nutrition and appetite regulation. The additional intake of protein often occurs in the form of supplements. One of the main ingredients used in sports and weight loss supplements are animal-derived proteins such as whey, which are of high quality, containing all the essential amino acids required in human nutrition with a high absorption rate. However, whey protein has a high environmental footprint, and it may contribute to insulin resistance in susceptible groups (e.g. obese, T2DM, insulin resistant, or those with sarcopenic obesity).
Rice and potato protein isolates are high-quality plant proteins containing all essential amino acids comparably to whey protein. These plant-derived proteins may provide a more sustainable and accessible alternative to animal-derived proteins for appetite regulation and weight management.
Detailed description
Intervention study with three treatment groups in a randomised, single-blind, triple crossover design.
Study population: Healthy male participants will receive three different isocaloric and -volumetric protein shakes prepared using whey, rice and potato protein powders on different trial days with at least a one-week washout period apart.
Biological samples (blood and saliva samples) are collected at various time points during the visit. Blood samples are collected at baseline 10 min prior (T-10), then at 30 min (T30), 60 min (T60), 120 min (T120) and at 180 min (T180) after protein shake consumption. Saliva samples are collected at baseline (T-10), then at every 30 minutes following protein shake consumption (T30, T60, T90, T120, T150, T180). In addition, pertinent questionnaires Visual Analogue Scale [VAS] for the assessment of satiety and VAS for the assessment of protein shakes' perception will be collected at T-10, T30, T60, T90, T120, T150, T180 and at T0, respectively
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 3
- Model description
- single-blind, randomised, triple crossover
| Arm | Type | Receives |
|---|---|---|
| Whey protein | Active comparator | Dietary Supplement: Whey protein isolateWhey protein isolate (45.5g total protein content) |
| Potato protein | Active comparator | Dietary Supplement: Potato protein isolatePotato protein isolate (45.3g total protein content) |
| Rice protein | Active comparator | Dietary Supplement: Rice protein isolateRice protein isolate (45.5g total protein content) |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Males (18-65 years of age)
- Healthy subjects
Key exclusion criteria (10 listed)
- <18 years or >65 years
- Consumption of >21 units of alcohol/week
- Dieters
- Any allergies/health issues related to items being ingested
- Any serious illnesses or those on medication
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Whey protein isolateInstantized BiPRO® 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake. Other ingredients in the whey protein shake: * Tropicana Trop50 Orange Juice 207mL * Water 43 mL * Sucralose 0.5g The total energy 233.47Kcal. Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study. | Dietary supplement | Whey protein |
| Potato protein isolateSolanic®100 48g (equiv. 45.3g of total protein) presented to participants in a form of a shake. Other ingredients in the potato protein shake: * Tropicana Trop50 Orange Juice 250mL * Sucralose 0.5g The total energy 233.46Kcal Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study. | Dietary supplement | Potato protein |
| Rice protein isolateOryzatein® Silk 90 50g (equiv. 45.5g of total protein) presented to participants in a form of a shake. Other ingredients in the rice protein shake: * Tropicana Trop50 Orange Juice 183mL * Water 67mL * Sucralose 0.5g The total energy 233.43Kcal Participants instructed to consume the entire protein shake presented to them in 5 minutes on an empty stomach when attending the study. | Dietary supplement | Rice protein |
Primary outcome
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T-10)
Time frame: Glucose measured 10 minutes prior to protein shake consumption
Marker: glucose (mmol/L)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T30)
Time frame: Glucose measured 30 minutes post protein shake consumption
Marker: glucose (mmol/L)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T60)
Time frame: Glucose measured 60 minutes post protein shake consumption
Marker: glucose (mmol/L)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T120)
Time frame: Glucose measured 120 minutes post protein shake consumption
Marker: glucose (mmol/L)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T180)
Time frame: Glucose measured 180 minutes post protein shake consumption
Marker: glucose (mmol/L)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T-10)
Time frame: Insulin measured 10 minutes prior to protein shake consumption
Marker: insulin (ng/mL)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T30)
Time frame: Insulin measured 30 minutes post protein shake consumption
Marker: insulin (ng/mL)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T60)
Time frame: Insulin measured 60 minutes post protein shake consumption
Marker: insulin (ng/mL)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T120)
Time frame: Insulin measured 120 minutes post protein shake consumption
Marker: insulin (ng/mL)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on insulin levels (T180)
Time frame: Insulin measured 180 minutes post protein shake consumption
Marker: insulin (ng/mL)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T-10)
Time frame: Glucagon-like peptide 1 measured 10 minutes prior to protein shake consumption
Markers: glucagon-like peptide 1 (pM)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T30)
Time frame: Glucagon-like peptide 1 measured 30 minutes post protein shake consumption
Markers: glucagon-like peptide 1 (pM)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T60)
Time frame: Glucagon-like peptide 1 measured 60 minutes post protein shake consumption
Markers: glucagon-like peptide 1 (pM)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T120)
Time frame: Glucagon-like peptide 1 measured 120 minutes post protein shake consumption
Markers: glucagon-like peptide 1 (pM)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucagon-like peptide 1 levels (T180)
Time frame: Glucagon-like peptide 1 measured 180 minutes post protein shake consumption
Markers: glucagon-like peptide 1 (pM)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T-10)
Time frame: Peptide tyrosine tyrosine measured 10 minutes prior to protein shake consumption
Markers: peptide tyrosine tyrosine (pg/mL)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T30)
Time frame: Peptide tyrosine tyrosine measured 30 minutes post protein shake consumption
Markers: peptide tyrosine tyrosine (pg/mL)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T60)
Time frame: Peptide tyrosine tyrosine measured 60 minutes post protein shake consumption
Markers: peptide tyrosine tyrosine (pg/mL)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T120)
Time frame: Peptide tyrosine tyrosine measured 120 minutes post protein shake consumption
Markers: peptide tyrosine tyrosine (pg/mL)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on peptide tyrosine tyrosine levels (T180)
Time frame: Peptide tyrosine tyrosine measured 180 minutes post protein shake consumption
Markers: peptide tyrosine tyrosine (pg/mL)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T-10)
Time frame: Ghrelin (pg/mL) measured 10 minutes prior to protein shake consumption
Markers: ghrelin (pg/mL)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T30)
Time frame: Ghrelin (pg/mL) measured 30 minutes post protein shake consumption
Markers: ghrelin (pg/mL)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T60)
Time frame: Ghrelin (pg/mL) measured 60 minutes post protein shake consumption
Markers: ghrelin (pg/mL)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T120)
Time frame: Ghrelin (pg/mL) measured 120 minutes post protein shake consumption
Markers: ghrelin (pg/mL)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on ghrelin levels (T180)
Time frame: Ghrelin (pg/mL) measured 180 minutes post protein shake consumption
Markers: ghrelin (pg/mL)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T-10)
Time frame: Visual Analogue Scale for Appetite (VAS-A) collected immediately prior to protein shake consumption
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T30)
Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 30 minutes after protein shake consumption
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T60)
Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 60 minutes after protein shake consumption
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T90)
Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 90 minutes after protein shake consumption
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T120)
Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 120 minutes after protein shake consumption
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T150)
Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 150 minutes after protein shake consumption
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on appetite (T180)
Time frame: Visual Analogue Scale for Appetite (VAS-A) collected 180 minutes after protein shake consumption
Subjective analysis including: Visual Analogue Scale for Appetite (VAS-A). Scores range from 0 to 100 (the higher the score the greater the level of appetite)
1 secondary outcome
To assess the perception of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO®
Time frame: VAS for Palatability collected immediately after protein shake consumption
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2021.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mohammed Gulrez Zariwala, PhD principal investigator
University of Westminster
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Whey protein isolate, Potato protein isolate and Rice protein isolate in people with Appetite and General Nutritional Disorders, run by University of Westminster at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 May 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To assess the acute effects of Solanic®100, Oryzatein® Silk 90 and Instantized BiPRO® on glucose levels (T-10) (time frame: Glucose measured 10 minutes prior to protein shake consumption). The study lists 32 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2021.